NCT05923372 (DALY-MAST) is a clinical trial in Mastocytosis, Indolent Systemic, sponsored by University Hospital, Toulouse.

Who is sponsoring NCT05923372?

NCT05923372 is sponsored by University Hospital, Toulouse.

What condition does NCT05923372 study?

NCT05923372 studies Mastocytosis, Indolent Systemic.

Is NCT05923372 still recruiting?

NCT05923372 is currently status unknown. Last updated 12 July 2023.

Last reviewed 2023-07-12 · How we verify

NCT05923372: DALY-MAST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the DALY on a Cohort of Patients With Indolent Systemic Mastocytosis

Status unknown Last updated 12 July 2023

What this trial tests

trial in Mastocytosis, Indolent Systemic in 160 participants. Status unknown.

Timeline

1 May 2023

Primary endpoint
1 May 2024

1 May 2024

Quick facts

Lead sponsor	University Hospital, Toulouse
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	160
Start date	1 May 2023
Primary completion	1 May 2024
Estimated completion	1 May 2024
Sites	1 location across France

Conditions studied

Mastocytosis, Indolent Systemic — all drugs for Mastocytosis, Indolent Systemic →

Sponsor

University Hospital, Toulouse

Who can join

18 and older, any sex, with Mastocytosis, Indolent Systemic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Mastocytosis is a group of pathologies characterized by the accumulation and/or clonal proliferation of abnormal mast cells in various organs. The impact of mastocytosis on health, quality of life, the psychoaffective sphere and on professional life constitutes the burden of this disease. The DALY is the disability-adjusted life expectancy, which takes into account the life expectancy and the number of years "lost" due to illness, disability or early death. Due to the major impact of the disease this study evaluates the DALY in indolent mastocytosis patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University Hospital, Toulouse trials

Trials by the same sponsor.

NCT07497750 — Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver D · NA · not yet recruiting
NCT07507240 — The Benefits of a Care Pathway Combining Remote Monitoring and Support From a Nurse After a Change in Anti-epileptic Tre · NA · not yet recruiting
NCT07524088 — Contamination of Young Children Hair During Acute Cannabis Intoxication · NA · not yet recruiting
NCT07470580 — Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension · NA · not yet recruiting
NCT07423988 — Evaluation of Changes in Sleep Efficiency Among PIC DU MIDI Staff Between Nights Spent at Home and Nights Spent in the W · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05923372 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Toulouse
Last refreshed: 12 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05923372.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing